Abstract
Head and Neck Squamous Cell Carcinomas (HNSCC) are a collection of tumors located in the upper aerodigestive tract that account for ∼500, 000 new cases annually. Onset of the disease in the population has been attributed to multiple environmental factors. Pathways leading to the development and progression of head and neck squamous cell carcinomas remain largely unknown. Common genetic alterations have been identified, but many of the important genes of activation (oncogenes) or inactivation (tumor suppressor genes) have not yet been identified or characterized. Epigenetic mechanisms, such as histone modifications and DNA methylation, have also become accepted modes of transcriptional inactivation in human malignancies, but are still in their initial stages of evaluation in HNSCC. The majority of DNA methylation studies in HNSCC have focused on genes previously identified as being inactivated in other cancer types. Efforts using genome-wide methylation scanning techniques, such as Restriction Landmark Genomic Scanning (RLGS), have identified novel methylation targets in HNSCC. Due to the involvement of DNA methylation, clinical trials involving demethylating agents, such as Decitabine, alone or in combination with chromatin modifying agents, remain attractive therapeutic options in cancer currently under investigation. Better understanding of the role of DNA methylation in squamous cell carcinomas of the head and neck, as well as the targets of this epigenetic inactivation, may allow for more efficient and earlier detection screenings. In this review, we will discuss our current understanding of epigenetic alterations in HNSCC and their potential use as targets for therapeutic intervention.
Keywords: dna methylation, neck squamous cell carcinomas, aerodigestive tract, epigenetic mechanisms
Current Genomics
Title: DNA Methylation Leaves Its Mark in Head and Neck Squamous Cell Carcinomas (HNSCC)
Volume: 5 Issue: 6
Author(s): L. T. Smith and C. Plass
Affiliation:
Keywords: dna methylation, neck squamous cell carcinomas, aerodigestive tract, epigenetic mechanisms
Abstract: Head and Neck Squamous Cell Carcinomas (HNSCC) are a collection of tumors located in the upper aerodigestive tract that account for ∼500, 000 new cases annually. Onset of the disease in the population has been attributed to multiple environmental factors. Pathways leading to the development and progression of head and neck squamous cell carcinomas remain largely unknown. Common genetic alterations have been identified, but many of the important genes of activation (oncogenes) or inactivation (tumor suppressor genes) have not yet been identified or characterized. Epigenetic mechanisms, such as histone modifications and DNA methylation, have also become accepted modes of transcriptional inactivation in human malignancies, but are still in their initial stages of evaluation in HNSCC. The majority of DNA methylation studies in HNSCC have focused on genes previously identified as being inactivated in other cancer types. Efforts using genome-wide methylation scanning techniques, such as Restriction Landmark Genomic Scanning (RLGS), have identified novel methylation targets in HNSCC. Due to the involvement of DNA methylation, clinical trials involving demethylating agents, such as Decitabine, alone or in combination with chromatin modifying agents, remain attractive therapeutic options in cancer currently under investigation. Better understanding of the role of DNA methylation in squamous cell carcinomas of the head and neck, as well as the targets of this epigenetic inactivation, may allow for more efficient and earlier detection screenings. In this review, we will discuss our current understanding of epigenetic alterations in HNSCC and their potential use as targets for therapeutic intervention.
Export Options
About this article
Cite this article as:
Smith T. L. and Plass C., DNA Methylation Leaves Its Mark in Head and Neck Squamous Cell Carcinomas (HNSCC), Current Genomics 2004; 5 (6) . https://dx.doi.org/10.2174/1389202043348940
DOI https://dx.doi.org/10.2174/1389202043348940 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Research Progress on the Antitumor Effects of Rhein: Literature Review
Anti-Cancer Agents in Medicinal Chemistry Mitosis-Targeting Natural Products for Cancer Prevention and Therapy
Current Drug Targets Needle in a Haystack: Targeting Specific Glucuronidases Amid the Human Microbiome
Current Enzyme Inhibition Meet Our Co-Editor Prof. Dr. Xiaofeng Charles Zhou
MicroRNA Ligand-Based Pharmacophore Modeling, Atom-Based 3D-QSAR and Molecular Docking Studies on Substituted Thiazoles and Thiophenes as Polo-Like Kinase 1 (Plk1) Inhibitors
Combinatorial Chemistry & High Throughput Screening Carbon Nanotubes as an Advanced Drug and Gene Delivery Nanosystem
Current Nanoscience From Natural Products to Designer Drugs: Development and Molecular Mechanisms Action of Novel Anti-Microtubule Breast Cancer Therapeutics
Current Topics in Medicinal Chemistry Cancer Stem Cell Model in Oral Squamous Cell Carcinoma
Current Stem Cell Research & Therapy Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design Inhibitors of the Hedgehog Signal Transduction Pathway
Current Cancer Therapy Reviews Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies
Clinical Cancer Drugs Dendritic Cells in Colorectal Cancer and a Potential for their Use in Therapeutic Approaches
Current Pharmaceutical Design Treatment Directed to Signalling Molecules in Patients with Advanced Differentiated Thyroid Cancer
Anti-Cancer Agents in Medicinal Chemistry Diagnostic and Therapeutic Applications of Recombinant Antibodies:Targeting the Extra-Domain B of Fibronectin, A Marker of Tumor Angiogenesis
Current Pharmaceutical Design Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Recent Progress in the Development of Fluorometric Chemosensors to Detect Enzymatic Activity
Current Medicinal Chemistry The Use of L-Glucose in Cancer Diagnosis: Results from In Vitro and In Vivo Studies
Current Medicinal Chemistry Role of Liprins in the Regulation of Tumor Cell Motility and Invasion
Current Cancer Drug Targets